TY - JOUR T1 - Anti-CELA1 KF4 Antibody Prevents Emphysema by Inhibiting Stretch-Mediated Remodeling JF - medRxiv DO - 10.1101/2020.04.27.20075531 SP - 2020.04.27.20075531 AU - Mohit Ojha AU - Noah Smith AU - Rashika Joshi AU - Emily Goodman AU - Qiang Fan AU - Richard Schuman AU - Aleksey Porollo AU - Rachel L. Zemans AU - Matthew R. Batie AU - Michael T. Borchers AU - Samuel Ammerman AU - Brian M. Varisco Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/04/18/2020.04.27.20075531.abstract N2 - Emphysema is a major contributor to the morbidity and mortality of chronic obstructive pulmonary disease (COPD), and there are no disease modifying therapies. Three leading pathophysiologic models are the altered protease/antiprotease balance model, the biomechanical model in which loss of one alveolar wall increases strain on adjacent wall predisposing them to failure, and the accelerated aging model. Chymotrypsin-like elastase 1 (CELA1) is a novel serine protease with a physiological role in reducing postnatal lung elastance that mechanistically links these three models. CELA1 is expressed by alveolar type 2 (AT2) cells and is found adjacent to lung elastin fibers. The KF4 antibody neutralizes CELA1 by binding to its catalytic triad. CELA1 binding to lung elastin fibers increases 4-fold with strain, and application of biaxial strain induces lung elastase activity which is blocked with the KF4 anti-CELA1 antibody. Cela1−/− mice were protected from airspace simplification in hyperoxia, elastase and cigarette-smoke induced emphysema, and age-related airspace simplification. CELA1 mRNA was correlated with human lung elastolytic activity, and anti-CELA1 KF4 antibody protected mice from hyperoxia-induced alveolar simplification and elastase emphysema. CELA1-mediated lung matrix remodeling in response to strain is an important contributor to postnatal airspace simplification. Matrix stabilization by KF4 represents a potential therapeutic approach to preventing emphysema progression.One Sentence Summary Neutralization of chymotrypsin-like elastase 1 prevents strain-induced emphysema.Competing Interest StatementPatents for use of anti-CELA1 therapies for alpha-1 antitrypsin-deficient emphysema and COPD.Funding StatementFunding: A1 Foundation Research Award 498262 (Varisco), NHBLI R01141229 (Varisco), NHLBI K08HL131261 (Varisco).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human tissue utilized under a waiver from the CCHMC IRB (2016-9641)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter peer-review publication, the data in this manuscript will be made available upon request. ER -